Table IV.
Post-chemotherapy and chemotherapy-induced AE-ILD.
| Patient | Age, years/sex | Histology | ILD pattern | AE-ILD (+/−) | Post-chemotherapy AE-ILD (+/−) |
|---|---|---|---|---|---|
| 1 | 67/M | SCC | Non-UIP | – | BSC |
| 2 | 67/M | SCC | UIP | – | BSC |
| 3 | 73/M | SCC | Non-UIP | – | 2nd-line S-1, 3rd-line nivolumab |
| 4 | 59/M | Undifferentiated | UIP | – | -Pemetrexed |
| 5 | 64/M | SCC | Non-UIP | – | +S-1 |
| 6 | 61/M | Undifferentiated | Non-UIP | – | -Docetaxel |
| 7 | 66/M | Undifferentiated | UIP | – | -BSC |
| 8 | 71/M | SCC | UIP | – | BSC |
| 9 | 76/M | SCC | UIP | – | -S-1 |
M, male; F, female; SCC, squamous cell carcinoma; AE, acute exacerbation; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; BSC, best supportive care.